Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
1. A method of eliciting an immune response in an acute myeloid leukemia patient, comprising administering to the patient a population of activated T cells that kill the cancer cells, which present a peptide consisting of the amino acid sequence of AEQFRLEQI (SEQ ID NO: 1), wherein the peptide is in a complex with an MHC class I molecule.
2. The method of claim 1 , wherein the T cells are autologous to the patient.
3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.
4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.
5. The method of claim 1 , wherein the activated T cells are expanded in vitro.
6. The method of claim 1 , wherein the MHC molecule is a class I or II MHC molecule.
7. The method of claim 1 , wherein the activated T cells are produced by contacting T cells with the peptide loaded human class I or II MHC molecules expressed on the surface of an antigen-presenting cell for a period of time sufficient to activate the T cells.
8. The method of claim 7 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.
9. The method of claim 8 , wherein the antigen presenting cell is a dendritic cell or a macrophage.
10. The method of claim 5 , wherein the expansion is in the presence of an anti-CD28 antibody and IL-12.
11. The method of claim 1 , wherein the population of activated T cells comprises CD8-positive cells.
12. The method of claim 1 , wherein the population of activated T cells are administered in the form of a composition.
13. The method of claim 12 , wherein the composition comprises at least one adjuvant.
14. The method of claim 13 , wherein the at least one adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivates, poly-(I:C) and derivates, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
15. The method of claim 1 , wherein the immune response is capable of killing cancer cells that present a peptide consisting of the amino acid sequence of AEQFRLEQI (SEQ ID NO: 1).
16. The method of claim 15 , wherein the immune response comprises a cytotoxic T cell response.
17. A method of treating an acute myeloid leukemia patient, comprising administering to the patient a population of activated T cells that kill the cancer cells, which present a peptide consisting of the amino acid sequence of AEQFRLEQI (SEQ ID NO: 1), wherein the peptide is in a complex with an MHC class I molecule.